ResMed (RMD) PT Raised to $240 at Oppenheimer as U-Shaped Recovery Continues
Tweet Send to a Friend
Oppenheimer analyst Suraj Kalia raised the price target on ResMed (NYSE: RMD) to $240.00 (from $212.00) after the company reported ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
